76129-28-7

Upstream product

• 1635-61-6 5-chloro-2-nitroaniline 
• 98-80-6 phenylboronic acid 
• 5228-61-5 5-bromo-2-nitroaniline 
• 92-93-3 1-phenyl-4-nitrobenzene 
• 854634-75-6 N-([1,1'-biphenyl]-3-yl)-4-methylbenzenesulfonamide 
• 2243-47-2 3-biphenyl amine 

Downstream Products

• 92-93-3 1-phenyl-4-nitrobenzene 
• 763131-39-1 6-phenyl-1,2,4-benzotriazin-3-amine 1-oxide 
• 905920-49-2 3-Iodo-4-nitro-1,1′-biphenyl 
• 1352638-01-7 3,4-dihydroxy-5-methoxy-N-(4-nitrobiphenyl-3-yl)benzamide 
• 1352637-81-0 3,4,5-trimethoxy-N-(4-nitrobiphenyl-3-yl)benzamide 
• 1449690-86-1 methyl 7-(6-phenyl-1H-benzo[d]imidazol-2-yl)heptanoate 
• 1179813-32-1 N-hydroxy-7-(5-phenyl-1H-benzo[d]imidazol-2-yl)heptanamide 
• 960307-41-9 C₂₇H₂₅N₃O₅ 
• 960307-26-0 C₂₇H₂₅N₃O₃ 
• 1449690-86-1 C₂₁H₂₄N₂O₂ 
• 90463-26-6 C₁₃H₁₀N₂ 

Relevant academic research and scientific papers

Tunneling and thermoelectric characteristics of N-heterocyclic carbene-based large-area molecular junctions

Reported herein are tunneling and thermoelectric characteristics of large-area molecular junctions formed with N-heterocyclic carbene (NHC)-based self-assembled monolayers on gold.

INK COMPOSITION FOR ORGANIC LIGHT-EMITTING DEVICE, ORGANIC LIGHT-EMITTING DEVICE INCLUDING FILM FORMED BY USING THE INK COMPOSITION, AND METHOD OF MANUFACTURING THE ORGANIC LIGHT-EMITTING DEVICE

An ink composition for an organic light-emitting device, the ink composition including a luminescent host material and a solvent, wherein the luminescent host material includes at least one compound represented by Formula (1), and wherein the solvent includes at least one selected from an aromatic ether, an aromatic ester, and an aromatic ketone: wherein, in Formula (1), groups and variables are the same as described in the specification.

COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, COMPOSITION FOR THE PRODUCTION OF ORGANIC ELECTROLUMINESCENT ELEMENT, AND ORGANIC ELECTROLUMINESCENT ELEMENT

PROBLEM TO BE SOLVED: To provide a novel and improved compound that can improve the thermal stability of an organic layer and extend the emission lifetime of an organic electroluminescent element, and an organic electroluminescent element material, a composition for the production of an organic electroluminescent element, and an organic electroluminescent element each of which comprises the compound. SOLUTION: The present invention provides a compound represented by general formula (1). SELECTED DRAWING: Figure 1 COPYRIGHT: (C)2017,JPOandINPIT

CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE CONDENSED CYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND, AND METHOD OF MANUFACTURING THE ORGANIC LIGHT-EMITTING DEVICE

A condensed cyclic compound represented by Formula (1): wherein, in Formula (1), groups and variables are the same as described in the specification.

Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents

A series of benzimidazole based HDAC inhibitors have been rationally designed, synthesized and screened. The SAR of this new chemotype is described. The lead compound, 11e, showed strong activity in several cellular assays and demonstrated in vivo efficacy in mouse xenograft pancreatic cancer models.

Potent galloyl-based selective modulators targeting multidrug resistance associated protein 1 and P-glycoprotein

The multifactorial nature of chemotherapy failure in controlling cancer is often associated with the occurrence of multidrug resistance (MDR), a phenomenon likely related to the increased expression of members of the ATP binding cassette (ABC) transporter superfamily. In this respect, the most extensively characterized MDR transporters include ABCB1 (also known as MDR1 or P-glycoprotein) and ABCC1 (also known as MRP1) whose inhibition remains a priority to circumvent drug resistance. Herein, we report how the simple galloyl benzamide scaffold can be easily and properly decorated for the preparation of either MRP1 or P-gp highly selective inhibitors. In particular, some gallamides and pyrogallol-1-monomethyl ethers showed remarkable affinity and selectivity toward MRP1. On the other hand, trimethyl ether galloyl anilides, with few exceptions, exhibited moderate to very high and selective P-gp inhibition.

TARGETING THE ONCOPROTEIN NUCLEOPHOSMIN

(+)-Avrainvillamide, a naturally occurring alkaloid with antiproliferative activity, is shown to bind to the oncoprotein nucleophosmin. Nucleophosmin is known to regulate the tumor suppressor protein p53 and is overexpressed in many different human tumors. The invention provides methods of modulating nucleophosmin and p53 using (+)-avrainvillamide and analogues thereof. These compounds may provide leads for the development of novel anti-cancer therapies that target nucleophosmin.

COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES

The invention encompasses a compound derived from hydroxamic acid that may be used to slow the expansion of cancer cells and thus is effective in the treatment of cancer. Generally, the disclosed compound includes a benzimidazole group coupled to a hydroxyamide of five or more unsubstituted carbon atoms and any pharmaceutically acceptable salts, solvates and chemically protected forms thereof. Also disclosed are pharmacological compositions including the compound and methods of using the compound to slow the expansion of cancer cells as well as methods of using the compound to treat cancer.

The natural product avrainvillamide binds to the oncoprotein nucleophosmin

Here we present evidence that (+)-avrainvillamide, a naturally occurring alkaloid with antiproliferative effects, binds to the nuclear chaperone nucleophosmin, a proposed oncogenic protein that is overexpressed in many different human tumors. Among other effects, nucleophosmin is known to regulate the tumor suppressor protein p53. A synthetic biotin-avrainvillamide conjugate, nearly equipotent to the natural product in inhibiting the growth of cultured T-47D cells, was used for affinity-isolation of a protein identified as nucleophosmin by MS sequencing and Western-blotting. Affinity-isolation of nucleophosmin was inhibited in the presence of iodoacetamide (10 mM), free (+)-avrainvillamide (100 μM), and a series of closely related structural analogues of (+)-avrainvillamide, the latter with inhibitory effects that appear to correlate with measured growth-inhibitory potencies. Using fluorescence microscopy, a synthetic dansyl-avrainvillamide conjugate was observed to localize within the nucleoli and the cytosol of treated cancer cells. Site-directed mutagenesis of each of the three cysteine residues of a truncated nucleophosmin coexpressed with native nucleophosmin in COS-7 cells revealed that the mutation cys275 -ala275 effectively and uniquely reduced affinity-isolation of the truncated protein, suggesting that avrainvillamide targets cys275 of nucleophosmin. Finally, we show that treatment of adhered LNCaP or T-47D cells with (+)-avrainvillamide leads to an increase in cellular p53 concentrations, and that siRNA-promoted depletion of nucleophosmin in a population of HeLa S3 cells leads to increased sensitivity of that population toward apoptotic death upon treatment with (+)-avrainvillamide. Although potentially desirable as lead compounds for the development of novel anticancer therapies, nonpeptidic, synthetic small molecules that bind to nucleophosmin have not been described, prior to this report.

Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity

Significant effort is being made to understand the role of HDAC isotypes in human cancer and to develop antitumor agents with better therapeutic windows. A part of this endeavor was the exploration of the 14 ? internal cavity adjacent to the enzyme catalytic site, which led to the design and synthesis of compound 4 with the unusual bis-(aryl)-type pharmacophore. SAR studies around this lead resulted in optimization to potent, selective, nonhydroxamic acid HDAC inhibitors.